Health Condition 1: null- Schizophrenia
Conditions
Interventions
Intervention1: Lurasidone: Tab lurasidone 40 mg OD
After four weeks of treatment, dose may be increased to lurasidone 80mg/day in case of insufficient improvement of schizophrenic symptoms as per
Sponsors
Dr Bhagyashree Mohod
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient of schizophrenia who is consulting first time to psychiatrist for the complaints 2. PANSS (positive and negative syndrome scale) score more than or equal to 80 3. Patient willing to give written informed consent.
Exclusion criteria
Exclusion criteria: Exclusion criteria :- 1)Pregnant, Nursing Women and children 2)Patients requiring other psychotropic medications, central nervous system active drugs 3)Patient with neurologic disorders (dementia, seizures, stroke), obesity , serious or not stabilized organic disorders (neoplasia, cardiovascular, pulmonary, uncontrolled type 1 or 2 diabetes) 4)Patients with any other psychiatric disorders 5)Abnormal renal/hepatic function
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the clinical efficacy of Lurasidone with Olanzapine in the treatment of schizophrenia with help of change in score on the positive and negative syndrome scale(PANSS) from baseline to week 12. Patient is responder when there will be reduction of more than or equal to 20% PANSS total score from baseline.Timepoint: 0 weeks to 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the safety profile of Lurasidone with Olanzapine by assessment of Liver Function Test, Lipid profile, blood glucose level and weight.Timepoint: At 0 week and 12 weeks | — |
Countries
India
Contacts
Public ContactDr Bhagyashree Mohod
Government Medical College Nagpur
Outcome results
None listed